LRX Command Center

Network revenue is $42.6M YTD, up 9.4% vs prior year driven by Baylor and Memorial Hermann specialty volume growth. Oncology contributes 41% of total revenue. Action: replicate Baylor formulary strategy across remaining sites to capture an additional $3.2M.

Total scripts at 18,420 this period, an 8.1% increase MoM. Growth is concentrated in immunology (+14%) and oncology (+11%) classes. New biosimilar launches added 340 incremental scripts. Monitor: staffing at Michigan Medicine may bottleneck further growth.

Network-wide PDC adherence is 87.3%, 2.7 pts below the 90% target. The gap is concentrated in newly enrolled patients during their first 90 days. SMS adherence PDSA at Baylor showed a 4.2 pt improvement. Recommendation: roll out SMS program to all sites.

Baylor leads at $12.4M (29% of network revenue), followed by Memorial Hermann at $9.8M. Providence trails at $6.1M, partially due to low capture rate. Closing the capture gap at Providence alone would add an estimated $2.8M annually. Action: prioritize Providence referral workflow improvements.

Oncology commands 38% of script volume, followed by Immunology at 27%. Rare Disease is the fastest-growing class at +22% QoQ despite low volume. Two new rare disease launches in Q2 could shift the mix meaningfully. Action: secure inventory commitments for anticipated rare disease demand.